Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19852462 | 0.79 | OPRM1 (0.40) | DRD2HTR7KMT2AMEN1HTR1A | |
| SCHEMBL19852300 | 0.78 | HTR7 (0.47) | DRD2HTR7KMT2AMEN1SIGMAR1 | |
| SCHEMBL19852152 | 0.77 | PDE4A (0.43) | SLC6A2CYP2D6SLC6A4DRD2HTR7 | |
| SCHEMBL19852349 | 0.77 | SIGMAR1 (0.52) | DRD2HTR7SIGMAR1HTR1ASMN1; SMN2 | |
| SCHEMBL19852298 | 0.77 | OPRM1 (0.35) | SLC6A2CYP2D6SLC6A4DRD2HTR7 | |
| SCHEMBL25619737 | 0.76 | LMNA (0.50) | DRD2SIGMAR1HTR1AEPHX2SMN1; SMN2 | |
| SCHEMBL21071614 | 0.76 | HTR7 (0.45) | DRD2HTR7KMT2AMEN1SIGMAR1 | |
| SCHEMBL19852460 | 0.71 | KCNH2 (0.46) | DRD2KMT2AMEN1SIGMAR1HTR1A | |
| SCHEMBL19374778 | 0.71 | SMN1; SMN2 (0.52) | SLC6A2CYP2D6DRD2KMT2AMEN1 | |
| SCHEMBL19852004 | 0.70 | KCNH2 (0.55) | DRD2KMT2AMEN1SIGMAR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | SLC6A2 5/4885CYP2D6 571/4885SLC6A4 15/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | SLC6A2 5/4885CYP2D6 571/4885SLC6A4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.